SCHEMBL13628209

SCHEMBL13628209

CS(=O)(=O)Nc1ccc2c(c1)N(Cc1cc(F)cc3c1OCOC3)C(=O)/C2=N\O

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AURKA O14965 3/20 0.39
KDR P35968 3/20 0.39
AURKB Q96GD4 3/20 0.39
NR3C1 P04150 2/20 0.35
POLB P06746 2/20 0.35
NPC1 O15118 1/20 0.35
RAB9A P51151 1/20 0.35
NPSR1 Q6W5P4 1/20 0.35
GALR3 O60755 1/20 0.35
NR2F2 P24468 1/20 0.35
MAPK8 P45983 1/20 0.35
PRF1 P14222 1/20 0.34
NR3C2 P08235 4/20 0.34
ALDH1A1 P00352 1/20 0.33
TDP1 Q9NUW8 1/20 0.33
HCRTR1 O43613 1/20 0.33
HCRTR2 O43614 1/20 0.33
PGR P06401 1/20 0.33
AR P10275 1/20 0.33
CA12 O43570 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13628210 0.93 AURKA (0.42) AURKAKDRAURKBPOLBNPC1
SCHEMBL13628211 0.91 BRD4 (0.38) AURKAKDRAURKBPOLBNPC1
SCHEMBL13628148 0.89 MAPK8 (0.37) KDRPOLBNPC1RAB9ANPSR1
SCHEMBL13628154 0.87 CA12 (0.36) AURKAKDRAURKBPOLBNPC1
SCHEMBL13628152 0.87 MAPK8 (0.39) POLBNPC1RAB9ANPSR1GALR3
SCHEMBL13628212 0.87 MAPT (0.40) AURKAKDRAURKBALDH1A1
SCHEMBL13628208 0.86 KDM4E (0.38) POLBNPC1RAB9ANPSR1GALR3
SCHEMBL13628308 0.86 MAPK8 (0.39) POLBNPC1RAB9ANPSR1GALR3
SCHEMBL13628063 0.85 POLB (0.38) POLBNPC1RAB9ANPSR1GALR3
SCHEMBL13628163 0.85 KDM4E (0.43) KDRPOLBNPC1RAB9ANPSR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7612065-B2 Inhibitors of c-JUN N-terminal kinases (JNK) VERTEX PHARMACEUTICALS INCORPORATED (US) 2009-11-03 US disclosed
US-7612065-B2 Inhibitors of c-JUN N-terminal kinases (JNK) VERTEX PHARMACEUTICALS INCORPORATED (US) 2009-11-03 US disclosed
US-20080033022-A1 Inhibitors of c-Jun N-terminal kinases (JNK) SALITURO FRANCESCO G 2008-02-07 US disclosed
US-20080033022-A1 Inhibitors of c-Jun N-terminal kinases (JNK) SALITURO FRANCESCO G 2008-02-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080033022-A1 Inhibitors of c-Jun N-terminal kinases (JNK) MAP3K1, JUN, MAP3K7 AURKA 1283/4885KDR 3535/4885AURKB 603/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.